The SAGE meeting of 9-11 April 2013 took place in Salle A of the CCV in Geneva. Available on this site you will find meeting information material and background reading materials. Presentations from the meeting will be made available soon. The conclusions and recommendations of SAGE meeting are published in the WHO Weekly Epidemiological Record in English and French within two months of each SAGE meeting.
Strategic Advisory Group of Experts on Immunization (SAGE) - April 2013
Related
Background documents and presentations
Session: Report from Director, IVB and regional reports
Background documents
Meeting of the Strategic Advisory Group of Experts on Immunization, November 2012 – conclusions and recommendations
Global Vaccine Action Plan - report by WHO secretariat to WHA, March 2013
Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial
Questions and Answers on Tuberculosis Vaccines - February 2013
WHO immunization highlights 2012
Presentations
Global report including key updates and challenges from regions - J.M. Okwo-Bele
Session: Reports from other advisory committees
Background documents
Report from the Global Advisory Safety Committee on Vaccine Safety (GACVS), December 2012
Report from the Immunization Practices Advisory Committee (IPAC) - Final meeting report and recommendations, 2-3 October 2012
Presentations
Report of the Global Advisory Committee on Vaccine Safety (GACVS) - M. Wharton
Report of the Immunization Practices Advisory Committee (IPAC) - S. Deeks
Session: Dengue
Background documents
Dengue vaccine candidates in clinical trials
Questions and Answers on Dengue Vaccines: Phase IIb study of CYD-TDV, September 2012
Guidelines on the quality, safety and efficacy of dengue tetravalent vaccines (live, attenuated)
Global strategy for dengue prevention and control 2010-2020
Vaccine journal article: Next generation dengue vaccines: A review of candidates in preclinical development
Presentations
Introduction to dengue epidemiology and disease burden - C. Simmons
Current status of dengue vaccine development-J. Roehrig
Critical issues for future vaccine introduction-P. Palihawadana
Session: Polio
Background documents
Report of the Independent Monitoring Board of the Global Polio Eradication Initiative - "Polio's Last Stand?", November 2012
Polio Eradication and Endgame Strategic Plan Executive Summary, 22 March 2013 (Draft)
New England Journal of Medicine article: Priming after a fractional dose of inactivated poliovirus vaccine, January 2013
Presentations
Polio Eradication and Endgame Strategic Plan: Issues for SAGE decisions in 2013-15-B. Aylward
Detection and interruption of poliovirus transmission: progress and contingency planning to address insecurity and social acceptance in the last endemic areas-H. Jafari
Planning for OPV2 withdrawal: status of pre-requisites and Polio Working Group priorities for 2013-14-E. Miller
Polio legacy planning in the Polio Strategic Plan 2013-2018-A. Freeman
Session: Yellow fever
Background documents
Background Paper on Yellow Fever Vaccine - SAGE Working Group
WHO position paper on yellow fever vaccine (October 2003)
Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: systematic review
SAGE Working Group on Yellow Fever Vaccine: Interference between YF vaccine and other vaccines, January 2012
Presentations
Introduction and status report on yellow fever control-O. Tomori
Evidence review with respect to the duration of protection and vaccine safety in special populations-E. Staples
Other evidence reviewed by the SAGE working group-A. Barrett
Session: Non-specific effects of vaccines
Background documents
Executive summary- Protocol epidemiology outcomes - Systematic Review of the Nonspecific Effects of BCG, DTP and measles containing vaccines on all-cause mortality in children under 5 years of age
Executive summary-Protocol immunology outcomes - - Systematic Review of the Nonspecific Effects of BCG, DTP and measles containing vaccines on all-cause mortality in children under 5 years of age
Systematic Review of the Nonspecific Effects of BCG, DTP and measles containing vaccines on deaths from infections other than those conditions that the given vaccine is designed to prevent and, on all-cause mortality in children under five years of age in children under 5 years of age
Systematic Review of the Nonspecific Effects of Selected Routine Childhood Immunization
Epidemiological studies of the ‘non-specific effects’ of vaccines: I – data collection in observational studies
Epidemiological studies of the non-specific effects of vaccines: II – methodological issues in the design and analysis of cohort studies
Presentations
Why are we reviewing the evidence on non-specific effects of vaccines on mortality in children under 5 years of age and update on the related SAGE working group?-T. Nolan
Sequence of vaccination in Low and Middle Income Countries – data from DHs and MICs surveys-C. Sanderson
Session: Vaccine hesitancy
Background documents
What influences vaccine acceptance: A model of determinants of vaccine hesitancy
SAGE Working Group on Vaccine Hesitancy – Literature Review
Vaccine hesitancy landscape analysis: List of key players working on the issue of vaccine hesitancy
Draft list of questions to assess vaccine hesitancy
Presentations
SAGE working group on vaccine hesitancy: terms of reference and process of work-P. Duclos on behalf of X. Liang
Vaccine hesitancy: definitions, scope, context specific causes and impact-B. Gellin
Strategies to address hesitancy, success and failures stories-S. Goldstein
Conclusions, recommendations and proposed way forward-P. Duclos on behalf of X. Liang
Session: GAVI
Background documents
GAVI Alliance board meeting, 4-5 December 2012, Dar es Salaam, Tanzania
Presentations
Session: Haemophillus Influenzae type b vaccines (Hib)
Background documents
What are optimal immunization schedules for Haemophilus influenzae type b vaccines (Hib) for children living in different epidemiological settings?
A systematic review of data from randomized controlled trials of childhood schedules
Haemophillus influenzae type b conjugate vaccine: Review of observational data on long term vaccine impact to inform recommendations for vaccine schedules
Presentations
Why are we reviewing the evidence on Hib vaccine and what are the questions for SAGE today?-J. Abramson
What evidence is available (from long term impact studies in 35 countries, observational studies and RCTs) on the number of doses, age at administration, interval between doses, duration of protection and combination vaccines?-R. Hajjeh
Adjusting the Impact and assessment of incremental benefits of various Hib vaccines schedules given the disease epidemiology and the actual age at vaccination-A. Clark
What are the optimal schedules for Hib vaccines for children living in different epidemiological settings?-J. Abramson
Session: Malaria
Background documents
Summary for SAGE by WHO secretariat with input from JTEG re: RTS,S/AS01 malaria vaccine
Report of the Fourth Meeting of the Joint Technical Expert Group (JTEG) on Malaria Vaccines in Pivotal Phase 3 Trials and Beyond, Geneva, Switzerland, 9-10 October 2012
A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
Questions and Answers on Malaria Vaccines, November 2012
RTS,S/AS01 vaccine summary tables of ongoing and planned studies
2013 Update to the Malaria Vaccine Technology Roadmap 2 (Draft)
Malaria vaccine technology roadmap
First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children
Presentations
Status of RTS,S/AS01 project-D. Kaslow
Assessment and critical issues for policy assessment-P. Smith
Updated Malaria Vaccine Roadmap and Development of malaria vaccine preferred product characteristics (for prevention of disease young children and for achievement of elimination) - V. Sathiyamoorthy